Skip to content

Boston Scientific BSX Proceeds From Issuance Of Senior Long Term Debt

Proceeds From Issuance Of Senior Long Term Debt at other companies

CONMED logo
CONMEDCNMD

Other financials

Income statement

See full
Revenue$5.4B+7.5%
Gross profit$3.8B+12.4%
Operating income$1.2B+43.8%
Net income$907.0M+14.1%
EPS (diluted)$0.61+15.1%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total debt$659.0M-94.1%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.3%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$68.43B-56.7%
P/E18.6×-44.6×
P/S3.3×-5.3×

Profitability

See full
Gross margin69.9%+1.7pp
Operating margin19.8%+2.8pp
Net margin17.5%+4.0pp
FCF margin16.9%-0.3pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt.

The official record: Boston Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Boston Scientific's proceeds from issuance of senior long term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Boston Scientific's proceeds from issuance of senior long term debt?
Boston Scientific (BSX) reported proceeds from issuance of senior long term debt of $0 in Q1 2026.
How has Boston Scientific's proceeds from issuance of senior long term debt changed year-over-year?
Boston Scientific's proceeds from issuance of senior long term debt decreased by 100.0% year-over-year, from $1.56B to $0.
What does proceeds from issuance of senior long term debt mean?
Cash inflows generated from the issuance of long-term debt securities, such as bonds or notes, to institutional investors. This represents a primary source of long-term capital for growth, acquisitions, or refinancing.